Cite
HARVARD Citation
Mie, T. et al. (2022). Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Japanese journal of clinical oncology. pp. 1399-1407. [Online].